rFVIIa + tranexamic acid

rFVIIa + tranexamic acid is a combination therapy approach investigated by Oslo University Hospital for the management of bleeding in hemophilia A patients with high-titer inhibitors. The combination pairs recombinant activated factor VII (rFVIIa), a bypassing agent that promotes hemostasis by activating factor X independently of factors VIII or IX, with tranexamic acid, a small molecule antifibrinolytic that prevents the degradation of fibrin clots. By simultaneously enhancing clot formation and inhibiting clot breakdown (fibrinolysis), this dual-action strategy aims to achieve superior clot stability and hemostatic efficacy compared to bypassing agents alone, particularly in patients who are poor responders to monotherapy. The approach was evaluated in a prospective crossover trial which demonstrated normalized clot stability without increasing thromboembolic risk.

Other names

recombinant activated factor VII + tranexamic acidNovoSeven + Cyklokaproneptacog alfa + tranexamic acid